Results 151 to 160 of about 2,780 (214)

Drug and alcohol detoxification: a needs assessment for Cork and Kerry. [PDF]

, 2006
Long, Jean
core  

Psychedelics in Multiple Sclerosis: Mechanisms, Challenges, and Prospects for Neuroimmune Modulation and Repair. [PDF]

Cells
Anchesi I, Astorino MF, Raffaele I, Donato DS, Silvestro S, Minuti A, Calabrò M, Scuruchi M, Cipriano GL.   +8 more
europepmc   +1 more source

v. 60, no. 10, April 2, 1992 [PDF]

, 1992

core   +1 more source

Extraction Yields of Psilocybin and Psilocin: A Short Review of Current Methods and Their Implications. [PDF]

Pharmaceuticals (Basel)
Galdino TP, Oliveira LC, Luz MA, Jesus RA, Lima EPN, Torres MCM, Sivieri K, Afonso VI, Delgado JMPQ, Lima AGB, Silva SML, Fook MVL.   +11 more
europepmc   +1 more source

Therapeutic and legal aspects of psilocybin in cancer-related depression. [PDF]

Front Psychiatry
Małgorzata W, Kopczyk R, Gerlach A, Rymaszewska J.   +3 more
europepmc   +1 more source

Psilocybin and Chronic Pain: A New Perspective for Future Pain Therapists? [PDF]

Med Sci (Basel)
Natoli S, Cuomo A, Marchesini M, Luongo L, Lo Bianco G, Guardamagna VA, Yamaguchi S.   +6 more
europepmc   +1 more source

Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action. [PDF]

Pharmacol Res Perspect
Kazdan J, Ladha KS, Husain MI.
europepmc   +1 more source

Molecular insights into the modulation of the 5HT_2A receptor by serotonin, psilocin, and the G protein subunit Gqα. [PDF]

FEBS Lett
Viohl N, Hakami Zanjani AA, Khandelia H.
europepmc   +1 more source

Targeting the 5-HT_2A Receptor for Developing Psychedelic Drugs and Beyond. [PDF]

J Med Chem
Ali S, Tian X, Cunningham KA, Zhou J.
europepmc   +1 more source